PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 17, 2026Journal for ImmunoTherapy of Cancer1 citationsOpen Access

Phase I Trial of CJRB-101 and Pembrolizumab in Metastatic Lung Cancer and Melanoma

Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJii Bum LeeSBSujeong BaekDKDong Kwon Kim

Discussion

Loading...

Member takes

Overview

Randomized trial shows antitumor response of CJRB-101 plus pembrolizumab in metastatic lung cancer, suggesting a new therapeutic avenue.

Key Points

  • This trial aims to evaluate the efficacy and safety of CJRB-101 combined with pembrolizumab in metastatic non-small cell lung cancer and other cancers.
  • Multicenter, open-label Phase I trial with a two-part design.
  • Involves patients with metastatic NSCLC, melanoma, and head and neck squamous cell carcinoma.
  • Utilizes doses of CJRB-101 and pembrolizumab, assessing toxicity and efficacy in ICI-naive and ICI-refractory cohorts.
  • In the ICI-naïve NSCLC cohort (n=12), the overall response rate (ORR) was 58% and disease control rate (DCR) was 75%.
  • For the ICI-refractory NSCLC group (n=22), ORR was 5% and DCR was 41%.
  • Median progression-free survival reported was 9 months for ICI-naïve patients and 1.8 months for ICI-refractory patients, with no patients experiencing grade > 3 treatment-related adverse events.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/6a095c037880e6d24efe1fe0https://doi.org/10.1136/jitc-2025-014702
View Full Paper
Ask AI
Bookmark
Share